Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068497 · ClinicalTrials.gov registry record · NA
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00068497: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00068497 is a NA study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068497, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for their growth
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068497
The ClinicalTrials.gov registry entry for NCT00068497 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00068497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068497 about?
NCT00068497 is a clinical study titled "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer". This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for their growth
What is the current status of trial NCT00068497?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00068497?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00068497?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.